Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of IPHA will rise by +3.28% over the next 2 Weeks and hit $1.49 by Thursday, May 14, 2026. In that time frame, IPHA's share price is expected to range between $1.33 and $1.63.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper |
|---|---|---|---|
| May 14, 2026 | 1.32 | 1.48 | 1.62 |
| May 13, 2026 | 1.30 | 1.46 | 1.61 |
| May 12, 2026 | 1.32 | 1.47 | 1.63 |
| May 11, 2026 | 1.33 | 1.48 | 1.63 |
| May 8, 2026 | 1.31 | 1.46 | 1.61 |
| May 7, 2026 | 1.31 | 1.47 | 1.61 |
| May 6, 2026 | 1.29 | 1.45 | 1.60 |
| May 5, 2026 | 1.31 | 1.47 | 1.62 |
| May 4, 2026 | 1.32 | 1.47 | 1.64 |
| May 1, 2026 | 1.30 | 1.45 | 1.60 |
IPHA shares fell -0.69% in Monday, May 4, 2026's trading session, dropping from a previous close of $1.44 to move at $1.43. The stock demonstrated notable intraday movement (see IPHA's key stats for a full breakdown), fluctuating between $1.43 and $1.57, a +9.79% trading range. While recent weeks have seen some volatility, IPHA has managed to secure a -13.86% drop over the past 2 weeks. The downward price movement was accompanied by decreased trading volume, with approximately 36.98K shares changing hands, 6.72K fewer than the previous session. This amounted to $52.88K in total market activity.
Will IPHA Continue Its Upward Trend?
According to analyst ratings and projections for IPHA, Innate Pharma S.A. shares are anticipated to increase by +11.94%, potentially reaching $1.62 per share by May 14, 2026. Short-term technical indicators currently suggest a neutral sentiment for IPHA. For deeper insights, view our sentiment analysis on AAPL covering social and institutional perspectives. However, the stock has recorded 13 positive trading days within the past 30 sessions. Based on the IPHA stock forecast, now is a good time to buy IPHA stock because its current trading price is -3.25% below our predicted value, hinting at a possible overvaluation. For deeper insights, view our sentiment analysis on IPHA covering social and institutional perspectives.
IPHA Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into IPHA's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 46.64% to 47.63%) suggest the stock is in a neutral to slightly bearish momentum phase. The 50-day RSI, at 46.39%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 46.90%, maintains a neutral outlook for the long term. Insights into IPHA's shareholder base show how institutional investors are positioning themselves during these momentum shifts
Innate Pharma SA Short-Term Forecasts
IPHA Forecast For Next 5 Days
Our algorithm anticipates Innate Pharma SA (IPHA) stock could hit $1.30 by May 11, 2026. This represents a -9.28% fall from today's price, following a -0.55% change over the past five days.
IPHA Forecast For Next 30 Days
Based on analysis of market trends, the outlook for Innate Pharma S.A. (IPHA) stock over the next 30 days is largely negative. Price forecasts suggest an average target of $1.26, which would mean a -11.89% decrease from the current price of $1.43. Projections for this period range from a high of $1.53 to a low of $0.99.
IPHA Forecast For Next 90 Days
Our proprietary market analysis suggests predictions for Innate Pharma SA's price over the next three months point to a rise. IPHA stock is expected to peak at $10.86 on May 26, 2026 before potentially dipping to $7.26 on Jul 09, 2026. On average, IPHA is likely to trade around $9.21 in the coming 90 days.
Innate Pharma SA Stock Forecast 2025
Based on our predictive models, Innate Pharma SA (IPHA) is expected to trade between $5.20 and $10.86 throughout 2026. This would result in an average price of $8.34, potentially offering investors a +483.22% return from current levels.
Innate Pharma S.A. Monthly Forecast 2026–2027
May 2026
According to our latest forecast models, Innate Pharma S.A. (IPHA) is positioned to show a strong performance in May 2026. The price is predicted to move between $9.51 and $10.86, settling at an average of $10.32. This could translate to a +621.68% gain.
June 2026
Based on current market signals, Innate Pharma S.A. is projected to trend june 2026. We forecast a trading range from $8.05 to $10.66, with a likely average price of $9.51. Investors could expect a potential return of +565.03%.
July 2026
Our predictive algorithms indicate Innate Pharma S.A. stock may see a shift in July 2026. The expected range spans $7.26–$9.00, with an average target of $8.06. This represents a positive outlook and a possible gain of +463.64%.
August 2026
Analyzing established trends, Innate Pharma S.A. looks set to move in August 2026. Projections place the stock between $8.06 and $8.97, averaging around $8.63. This suggests a +503.50% gain from current levels.
September 2026
Market indicators suggest Innate Pharma S.A. could experience notable changes during September 2026. Prices could fluctuate within $7.33 to $8.54, with a midpoint forecast of $7.97. The stock might deliver a +457.34% gain.
October 2026
Forecasting for October 2026, models estimate that Innate Pharma S.A. may undergo key fluctuations. If trends hold, the stock might trade between $7.40 and $9.13, averaging $8.32. This signals a positive trajectory with potential returns around +481.82%.
November 2026
According to our latest forecast models, Innate Pharma S.A. (IPHA) is positioned to show a strong performance in November 2026. The price is predicted to move between $5.35 and $9.04, settling at an average of $7.39. This could translate to a +416.78% gain.
December 2026
Based on current market signals, Innate Pharma S.A. is projected to trend december 2026. We forecast a trading range from $5.20 to $8.07, with a likely average price of $6.84. Investors could expect a potential return of +378.32%.
January 2027
Our predictive algorithms indicate Innate Pharma S.A. stock may see a shift in January 2027. The expected range spans $4.48–$7.99, with an average target of $6.74. This represents a positive outlook and a possible gain of +371.33%.
February 2027
Analyzing established trends, Innate Pharma S.A. looks set to move in February 2027. Projections place the stock between $4.06 and $6.82, averaging around $5.97. This suggests a +317.48% gain from current levels.
March 2027
Market indicators suggest Innate Pharma S.A. could experience notable changes during March 2027. Prices could fluctuate within $3.42 to $6.82, with a midpoint forecast of $6.16. The stock might deliver a +330.77% gain.
April 2027
Forecasting for April 2027, models estimate that Innate Pharma S.A. may undergo key fluctuations. If trends hold, the stock might trade between $2.47 and $6.51, averaging $5.51. This signals a positive trajectory with potential returns around +285.31%.
May 2027
According to our latest forecast models, Innate Pharma S.A. (IPHA) is positioned to show a strong performance in May 2027. The price is predicted to move between $2.36 and $5.32, settling at an average of $4.91. This could translate to a +243.36% gain.
IPHA's history of dividends and stock splits also plays a role in long-term investor confidence.